Business
Avalon GloboCare Expands AVA-Trap™ Program to Treat COVID-19 and CAR-T Related Cytokine Storms
Expands and files two USPTO provisional patent applications jointly with the Massachusetts Institute of Technology (MIT) Media Lab to develop a
About this update from Avalon Globocare Corp.
[{"type":"text","content":"Expands and files two USPTO provisional patent applications jointly with the Massachusetts Institute of Technology (MIT) Media Lab to develop a cytokine-specific blood purification system based on Avalon’s proprietary AVA-Trap™ technologyReflects advancements to Avalon’s AVA-Trap™ blood filtration system designed to rid the body of cytokines unleashed during the “cytokine storm” and acute respiratory distress syndrome (ARDS) in COVID-19 patients, as well as cancer patients treated with CAR T-cell therapy and other patients that require rapid removal of cytokines from the body The expanded patent application combines two novel technologies—S-layers and a protein design code tool—for a decoy cytokine receptor system to filter out pro-inflammatory cytokine levels in the blood in those experiencing cytokine storm FREEHOLD, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that Avalon has expanded and filed two provisional patents with the U.S. Patent and Trademark Office outlining compositions and methods of developing a decoy cytokine receptor-based filter system to treat “cytokine storms.” These provisional patent applications are direct results of recent advancements related to Avalon’s AVA-Trap™ therapeutic program. The technology utilizes cytokine receptor–Fc-fusion proteins to potentially serve as an antibody-like decoy to dampen the excessive cytokine release that occurs during hyper-activation of the immune system—a life-threatening condition called “cytokine storm” that can cause multi-organ failure and death. \n Patients infected with the SARS-CoV-2 virus that causes COVID-19 are susceptible to developing cytokine storms, which occur when the immune system suddenly produces high levels of inflammatory proteins called cytokines that concentrate in the blood. The extracorporeal hemo-purifier device is designed to provide potential treatment for patients experiencing cytokine storms induced by COVID-19, hepatitis, HIV, influenza, graft-versus-host disease, and cytokine release syndrome associated with CAR-T cell therapy. The expanded patent application was jointly filed with Professor Shuguang Zhang of the Massachusetts Institute of Technology (MIT) Media Lab, and Professor Uwe Sl...